|
| Status |
Public on Jan 01, 2021 |
| Title |
Identification of Lead Drug Candidates for COVID-19 based on Drug Screening Using Human Pluripotent Stem Cell-Derived Cells/Organoids |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
We systematically probed which cell types are permissive to SARS-CoV-2 infection. Transcriptomic analysis following SARS-CoV-2 infection of hPSC-derived lung organoids revealed upregulation of chemokines but not type I/III interferon signaling, similar to what was seen in primary human COVID-19 pulmonary infection.
|
| |
|
| Overall design |
Transcriptomic analysis of stem cell derived lung organoids
|
| |
|
| Contributor(s) |
Schwartz R, Chen S, Chen HJ, tenOever B, Redmond D |
| Citation(s) |
32511403 |
| |
| Submission date |
Apr 15, 2020 |
| Last update date |
Feb 11, 2021 |
| Contact name |
David Redmond |
| E-mail(s) |
dar2042@med.cornell.edu
|
| Organization name |
Weill Cornell Medicine
|
| Street address |
1300 York Avenue
|
| City |
New York |
| State/province |
New York |
| ZIP/Postal code |
10065 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (6)
|
| GSM4476798 |
Infected cells from lung for the study of SAR-CoV-2, 1 |
| GSM4476799 |
Infected cells from lung for the study of SAR-CoV-2, 2 |
| GSM4476800 |
Infected cells from lung for the study of SAR-CoV-2, 3 |
|
| Relations |
| BioProject |
PRJNA625444 |
| SRA |
SRP256442 |
Less...
More...